APRE
NASDAQAprea Therapeutics Inc.
Price$0.93+0.03 (+2.96%)
04:45 PM07:45 PM
News · 26 weeks50+22%
2025-10-262026-04-19
Mix3390d
- SEC Filings13(39%)
- Other10(30%)
- Insider6(18%)
- Leadership3(9%)
- Offering1(3%)
Latest news
25 items- SECSEC Form S-3 filed by Aprea Therapeutics Inc.S-3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual MeetingDOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract "Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)" at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL. Presentation Details:Title:Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in
- SECSEC Form PRE 14A filed by Aprea Therapeutics Inc.PRE 14A - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRFrazier Life Sciences Appoints Christian Schade as Senior AdvisorFrazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Christian Schade as Senior Advisor. Chris will join FLS' Boston office and work closely with the firm's portfolio companies on corporate strategy and business development. "Chris brings deep operational and financial experience with both private and public biopharma companies," said Joe Cabral, Partner at Frazier Life Sciences. "His leadership experience and ability to guide companies through critical inflection points make him a strong addition to our advisory team. We're pleased to welcome him as we continue building out our Boston team." Mr. Schade joins
- INSIDERSEC Form 4 filed by Hamill John P.4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERSEC Form 4 filed by Peters Richard4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementDOYLESTOWN, Pa., April 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the closing of its previously announced oversubscribed private placement financing. Total gross proceeds from the offering are approximately $30 million to the Company before deducting placement agent fees and other private placement expenses (the "Offering"). The Offering closed on March 31, 2026. The Company intends to use the upfront net proceeds for general corporate purposes and for research a
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Announces Oversubscribed $30 Million Private PlacementFinancing led by Soleus Capital with participation from Vestal Point Capital, Squadron Capital Management and additional new and existing investors DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it has entered into a securities purchase agreement for an oversubscribed private placement financing that is expected to result in total gross proceeds of approximately $30 million to the Company before deducting placement agent fees and other pr
- PRAprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 TrialConfirmed partial response at 220 mg indicates anti-tumor activity of APR-1051 in biomarker-defined cancersEarly clinical data suggest the potential of APR-1051 as a best-in-class WEE1 inhibitorEmerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic indexA further update from the trial is expected in the second quarter of 2026 DOYLESTOWN, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for
- SECSEC Form EFFECT filed by Aprea Therapeutics Inc.EFFECT - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form 424B3 filed by Aprea Therapeutics Inc.424B3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECAmendment: SEC Form S-3/A filed by Aprea Therapeutics Inc.S-3/A - Aprea Therapeutics, Inc. (0001781983) (Filer)
- INSIDERPresident/CEO Gilad Oren was granted 20,175 shares, increasing direct ownership by 5% to 393,895 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- INSIDERSrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. was granted 10,095 shares, increasing direct ownership by 30% to 43,528 units (SEC Form 4)4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)
- SECSEC Form S-8 filed by Aprea Therapeutics Inc.S-8 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECSEC Form 10-K filed by Aprea Therapeutics Inc.10-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateEarly clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical developmentCapital is in place to support key milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial DOYLESTOWN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targe
- SECSEC Form S-3 filed by Aprea Therapeutics Inc.S-3 - Aprea Therapeutics, Inc. (0001781983) (Filer)
- SECAprea Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)
- PRAprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 TrialTumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose levelPatient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A mutation, supporting mechanistic thesis of targeting WEE1 for this patient population Emerging clinical proof of concept responses without class-limiting toxicity to date support Aprea's development strategy of differentiated WEE1 inhibition with an improved therapeutic index DOYLESTOWN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific v
- PRAprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, to take place February 25-26, 2026, virtually. Presentation Details Date/ time:February 26, 2026 8:40 am ESTLocation: VirtualWebcast link: click here The webcast will be available for 90 days at the link above or on the Investors page of the Aprea c
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)